Adjuvant therapy of T1 bladder carcinoma: preliminary results of an EORTC randomized study.
This paper reports the preliminary results of an ongoing clinical trial in patients with category T1 bladder cancer who are randomized after transurethral resection to receive either thiotepa, VM-26, or no treatment. While there are no significant differences between the three treatment groups with respect to the time until first recurrence, thiotepa has significantly reduced the recurrence rate as compared to either VM-26 (P = 0.03) or no treatment (P = 0.04) among the 215 patients for whom follow-up information is currently available.
D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010336:Pathology; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011897:Random Allocation; D013713:Teniposide / Q000627:therapeutic use*; D013852:Thiotepa / Q000627:therapeutic use*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery*
D013852:Thiotepa; D013713:Teniposide; D011034:Podophyllotoxin